Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu y Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Madrid, Spain.
Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK; Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
Lancet Neurol. 2021 Nov;20(11):930-942. doi: 10.1016/S1474-4422(21)00245-3.
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.
唐氏综合征患者会出现阿尔茨海默病的神经病理学特征,并面临极高的早发性痴呆风险,目前该病已成为该人群的主要致死原因。由于该人群缺乏经过验证的诊断标准,且与唐氏综合征相关的智力障碍会掩盖症状,因此痴呆的诊断仍然是一个临床挑战。在唐氏综合征患者中,液体和成像生物标志物已显示出良好的诊断性能,并且其变化的时间进程与散发性和常染色体显性阿尔茨海默病非常相似。最重要的是,目前尚无预防阿尔茨海默病的方法,尽管唐氏综合征患者可能是进行阿尔茨海默病预防试验的最佳人群。唐氏综合征领域前所未有的研究活动正在迅速改变这种黯淡的局面,这将转化为能够使其他人群受益的疾病修饰疗法。